Nuclear factor erythroid 2-related factor gene variants and susceptibility of arsenic-related skin lesions

Human and Experimental Toxicology

Volumn 33, Issue 6, 2014, Pages 582-589

  Cordova, E J ^a   Valenzuela, O L ^b   Sanchez Pena L C ^b   Escamilla Guerrero, G ^c   Hernandez Zavala A ^b   Orozco, L ^a,d   Razo, Lm Del ^b  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DE LA CIUDAD DE MÉXICO   (Mexico)

Author keywords

Arsenic; NRF2; skin lesions

Indexed keywords

ARSENIC; DRINKING WATER; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN; WATER POLLUTANT;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CASE CONTROL STUDY; CHEEK; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; TRANSCRIPTION INITIATION; WATER CONTAMINATION; ADOLESCENT; ADVERSE EFFECTS; ARSENIC POISONING; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHENOTYPE; PROTECTION; RISK FACTOR; SKIN DISEASES; WATER POLLUTANT; YOUNG ADULT;

ADOLESCENT; ADULT; ARSENIC; ARSENIC POISONING; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTECTIVE FACTORS; RISK FACTORS; SKIN DISEASES; WATER POLLUTANTS, CHEMICAL; YOUNG ADULT;

EID: 84901386299     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327113506234     Document Type: Article

References (41)

1. Amini M, Abaspour KC, Berg M, et al. Statistical modeling of global geogenic arsenic contamination in groundwater. Environ Sci Technol. 2008 ; 42: 3669-3675 (Pubitemid 351694076)
2. Fernández MI, López JF, Vivaldi B, Coz F. Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J Urol. 2012 ; 187: 856-861
3. Shi H, Shi X, Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem. 2004 ; 255: 67-78 (Pubitemid 38159766)
4. Hsieh YC, Lien LM Chung WT, et al. Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ Res. 2011 ; 111: 804-810
5. Maull EA, Ahsan H, Edwards J, et al. Evaluation of the association between arsenic and diabetes: a national toxicology program workshop review. Environ Health Perspect. 2012 ; 120: 1658-1670
6. IARC monograph. Available at: http://monographs.iarc.fr/ENG/Monographs/ vol100C/index.php(accessed 20 december 2012).
7. Zhou X, Sun X, Cooper KL, et al. Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J Biol Chem. 2011 ; 286: 22855-22863
8. Smeester L, Rager JE, Bailey KA, et al. Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 ; 24: 165-167
9. Zhang Z, Wang X, Cheng S, et al. Reactive oxygen species mediate arsenic induced cell transformation and tumorigenesis through Wnt/β-catenin pathway in human colorectal adenocarcinoma DLD1 cells. Toxicol Appl Pharmacol. 2011 ; 256: 114-121
10. Hernández A, Marcos R. Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Pharmacogenomics. 2008 ; 9: 1113-1132
11. Beebe-Dimmer JL, Lyer PT, Nriagu JO, et al. Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study. Environ Health. 2012 ; 11: 11-43
12. Wu MM, Chiou HY, Chen CL, et al. GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. Toxicol Appl Pharmacol. 2010 ; 248: 226-233
13. Copple IM. The KEAP1-NRF2 cell defense pathway: a promising therapeutic target?. Adv Pharmacol. 2012 ; 63: 43-79
14. Kobayashi A, Ohta T, Yamamoto M. Unique function of the NRF2-KEAP 1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol. 2004 ; 378: 273-286
15. Zhang DD, Lo SC, Cross JV, et al. Keap 1 is redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cel Biol. 2004 ; 24: 10941-10953 (Pubitemid 39603148)
16. Tanaka Y, Aleksunes LM, Goedken MJ, et al. Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicol Appl Pharmacol. 2008 ; 231: 364-373
17. Malhotra D, Portales-Casamar E, Singh A, et al. Global mapping of binding sites for NRF2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010 ; 38: 5718-5734
18. Uruno A, Motohashi H. The KEAP1-NRF2 system as an in vivo sensor for electrophiles. Nitric Oxide. 2011 ; 25: 153-160
19. Wang XJ, Sun Z, Chen W, et al. Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity. Toxicol Appl Pharmacol. 2007 ; 225: 206-213 (Pubitemid 350088062)
20. Shinkai Y, Sumi D, Fukami I, et al. Sulforaphane, an activator of Nrf2, suppresses cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. FEBS Lett. 2006 ; 580: 1771-1774
21. Zhao R, Hou Y, Zhang Q, et al. Cross-regulations among NRFs and KEAP1 and effects of their silencing on arsenic-induced antioxidant response and cytotoxicity in human keratinocytes. Environ Health Perspect. 2012 ; 120: 583-589
22. Abiko Y, Shinkai Y, Sumi D, et al. Reduction of arsenic-induced cytotoxicity through Nrf2/HO-1 signaling in HepG2 cells. Journal of Toxicol Sci. 2010 ; 35: 419-423
23. Jiang T, Huang Z, Chan JY, et al. Nrf2 protects against As(III)-induced damage in mouse liver and bladder. Toxicol Appl Pharmacol. 2009 ; 240: 8-14
24. Yamamoto T, Yoh K, Kobayashi A, et al. Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun. 2004 ; 321: 72-79 (Pubitemid 39055607)
25. Fukushima-Uesaka H, Saito Y, Maekawa K, et al. Genetic variations and haplotype structures of transcriptional factor Nrf2 and its cytosolic reservoir protein Keap1 in Japanese. Drug Metab Pharmacokinet. 2007 ; 22: 212-219
26. Arisawa T, Tahara T, Shibata T, et al. Association between promoter polymorphism of nuclear factor erytrhoid 2-ralted factor 2 gene and peptic ulcer diseases. Int J Mol Med. 2007 ; 20: 849-853
27. Marzec JM, Christie JD, Reddy SP, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J. 2007 ; 21: 2237-2246 (Pubitemid 47026458)
28. Córdova EJ, Velázquez-Cruz R, Centeno F, et al. The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus. 2010 ; 19: 1237-1242
29. Yeh S. Skin cancer in chronic arsenicism. Hum Pathol. 1973 ; 4: 469-485
30. Valenzuela OL, Borja-Aburto VH, García Vargas GG, et al. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect. 2005 ; 113: 250-254 (Pubitemid 40450653)
31. Valenzuela OL, Germolec DR, Borja-Aburto, et al. Chronic arsenic exposure increases TGF alpha concentration in bladder urothelial cells of mexican populations environmentally exposed to inorganic arsenic. Toxicol Appl Pharmacol. 2007 ; 222: 264-270 (Pubitemid 47208517)
32. Del Razo LM, Arellano MA, Cebrian ME. The oxidation states of arsenic in well-water from a chronic arsenicism area of northern Mexico. Environ Pollut. 1990 ; 64: 143-153 (Pubitemid 20201042)
33. Del Razo LM, Styblo M, Cullen WR, et al. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol. 2001 ; 174: 282-293 (Pubitemid 32747839)
34. Devesa V, Razo LMD, Adair B, et al. Comprehensive analysis of arsenic metabolites by pH-specific hydride generation atomic absorption spectrometry. J Anal Atom Spectrom. 2004 ; 19: 1460-1467
35. Jomova K, Jenisova Z, Feszterova M, et al. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011 ; 31: 95-107
36. Lesseur C, Gilbert-Diamond D, Andrews AS, et al. A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire. Toxicol Lett. 2012 ; 210: 100-106
37. Huang CY, Su CT, Chu JS, et al. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area. Toxicol Appl Pharmacol. 2011 ; 257: 349-355
38. Sibhatu MB, Smitherman PK, Townsend AJ, et al. Expression of MRP1 and GSTP1-1 modulate the acute cellular response to treatment with the chemopreventive isothiocyanate, sulforaphane. Carcinogenesis. 2008 ; 29: 807-815 (Pubitemid 351494169)
39. Maher JM, Dieter MZ, Aleksunes LM, et al. Oxidative and electrophilic stress induces multidrug resis-tance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 ; 46: 1597-1610 (Pubitemid 350155541)
40. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet. 2001 ; 27: 234-236 (Pubitemid 32201838)
41. Von Otter M, Landgren S, Nilsson S, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet. 2010 ; 11: 36-45